Denemek ALTIN - Özgür

Fintechs had ample time to comply with regulations

Business Standard

|

November 08, 2024

Regulations surrounding financial technology (fintech) companies have evolved over time, giving firms ample opportunity to comply. Now, these companies must prioritize corrective actions as they scale operations, industry players said at the Business Standard BFSI Insight Summit 2024.

- AJINKYA KAWALE & ANJALI SINGH

Fintechs had ample time to comply with regulations

In recent years, India's fintech ecosystem has grown to become the third-largest in the world, with over 10,000 entities operating in the country. This growth, however, has brought major challenges, primarily in terms of compliance with regulatory guidelines.

During a panel discussion titled 'Navigating the Future of Fintech: Innovation, Regulation, and Growth', industry participants acknowledged that the sector has come to recognize the importance of innovation that aligns with regulatory spirit.

"Mistakes are made when firms are young. It is now time to correct those mistakes once and for all. The work required to do that demands considerable effort and intelligence, including processes and people," said Akshay Mehrotra, co-founder and chief executive officer (CEO) of Fibe (formerly EarlySalary), a Pune-based lending fintech firm.

Industry players said that regulatory bodies in India engage in private deliberations with firms, scrutinizing and evaluating them before taking any supervisory action.

"The industry is undergoing an evolution. Regulators have given fintech companies and the broader financial services sector ample time to adapt over the past few years. While regulators tend to be conservative on many matters, they are very calculated in their actions," said Anurag Jain, founder and chief operating officer of KredX, a micro, small and medium enterprise financing platform.

Business Standard'den DAHA FAZLA HİKAYE

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size